NGI And Harapan Kita Hospital Present More Accurate Prenatal Screening

JAKARTA PT Naleya Genomik Indonesia (NGI) and Harapan Kita Children's and Mother Hospitals (RSAB) are officially collaborating in the Extended Non-Invasive Prenatal Test (NIPT-Pro) and CNVseq (Copy Number Variations Sequencing) research.

President Director of PT Naleya Genomik Indonesia, Heru Dharmadi, explained that CNVseq technology is the first prenatal diagnostic innovation in Indonesia designed to provide comprehensive detection of chromodynamic disorders, including aneuploidi, triploidi, and various types of CNV abnormalities.

"With a high level of accuracy, this technology plays an important role in supporting the right clinical decision-making to maintain the health of the mother and fetus," Heru said in his statement, Tuesday, February 18.

Heru Dharmadi explained that this research was designed to test NIPT-Pro, a genetic test based on massively parallel sequencing technology, in detecting aneuploidy in chromosomes and Copy Number Variations (CNV) in the population of pregnant women in Indonesia.

"In its implementation, the results of the NIPT-Pro with high risk as well as ultrasound findings that indicate that the risk will be further confirmed using CNV sequencing (CNVseq) technology in the digestive fluid of the pregnant woman concerned," added Heru.

Meanwhile, the President Director of Harapan Kita Hospital, dr. Ockti Palupi Rahayuningtyas, welcomed this collaboration because it can provide significant benefits for pregnant women in Indonesia in obtaining early detection of fetal genetic disorders.

"We hope this research can be the first step in developing more sophisticated, accurate, and fast prenatal screening and diagnostics and making NIPT an alternative modality for genomic fetal evaluation as a universal first level screening for pregnant women," he said.

Ockti added that this program is expected to be in line with the pillars of the health transformation carried by the Ministry of Health of the Republic of Indonesia, especially the transformation of health technology.

With this innovation, pregnant women in Indonesia can access a more secure, accurate, comprehensive, and affordable prenatal screening method to anticipate and plan the handling of genetic disorders during pregnancy and pregnancy.

Non-Invasive Prenatal Testing (NIPT) is a genetic screening method that aims to assess the risk of chromodynamic disorders in the fetus from an early age, starting the 10th week of pregnancy.

NIPT can analyze the DNA of the fetus found in the mother's blood to detect the risk of chromodynamic disorders such as Down syndrome (Trisomi 21), Edwards syndrome (Trisomi 18), and Patau syndrome (Trisomi 13) using Next-Generation Sequencing technology.

The NIPT-Pro as an expanded version allows the detection of additional chromodynamic disorders, including microdelesy syndrome and microduplics.

Through this study, NGI and Harapan Kita Hospital are committed to providing more accurate and wider accessable prenatal diagnostic innovations for pregnant women in Indonesia.

The signing of this collaboration was also witnessed by the Director General of Pharmacy and Medical Devices, Dr. Dr. Lucia Rizka Andalucia, Director General of Advanced Health, Dr. Azhar Jaya, and Co-Founder and Chairman of BGI Group, Dr. Wang Jian, as a form of support for the development of prenatal genetic screening technology in Indonesia.